DOCSLIB.ORG

Met Receptor Tyrosine Kinase Signals Through a Cortactin–Gab1 Scaffold

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Met Receptor Tyrosine Kinase Signals Through a Cortactin–Gab1 Scaffold 2940 Research Article Met receptor tyrosine kinase signals through a cortactin–Gab1 scaffold complex, to mediate invadopodia Charles V. Rajadurai1,2, Serhiy Havrylov2,3,*, Kossay Zaoui2,3,*, Richard Vaillancourt1,2, Matthew Stuible1,2, Monica Naujokas2, Dongmei Zuo2, Michel L. Tremblay1,2 and Morag Park1,2,3,4,` 1Department of Biochemistry, McGill University, Montre´al, Que´bec H3A 1Y6, Canada 2Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montre´al, Que´bec H3A 1A3, Canada 3Department of Medicine, McGill University, Montre´al, Que´bec H3A 1A1, Canada 4Department of Oncology, McGill University, Montre´al, Que´bec H3A 1A1, Canada *These authors contributed equally to this work `Author for correspondence ([email protected]) Accepted 23 January 2012 Journal of Cell Science 125, 2940–2953 ß 2012. Published by The Company of Biologists Ltd doi: 10.1242/jcs.100834 Summary Invasive carcinoma cells form actin-rich matrix-degrading protrusions called invadopodia. These structures resemble podosomes produced by some normal cells and play a crucial role in extracellular matrix remodeling. In cancer, formation of invadopodia is strongly associated with invasive potential. Although deregulated signals from the receptor tyrosine kinase Met (also known as hepatocyte growth factor are linked to cancer metastasis and poor prognosis, its role in invadopodia formation is not known. Here we show that stimulation of breast cancer cells with the ligand for Met, hepatocyte growth factor, promotes invadopodia formation, and in aggressive gastric tumor cells where Met is amplified, invadopodia formation is dependent on Met activity. Using both GRB2- associated-binding protein 1 (Gab1)-null fibroblasts and specific knockdown of Gab1 in tumor cells we show that Met-mediated invadopodia formation and cell invasion requires the scaffold protein Gab1. By a structure–function approach, we demonstrate that two proline-rich motifs (P4/5) within Gab1 are essential for invadopodia formation. We identify the actin regulatory protein, cortactin, as a direct interaction partner for Gab1 and show that a Gab1–cortactin interaction is dependent on the SH3 domain of cortactin and the integrity of the P4/5 region of Gab1. Both cortactin and Gab1 localize to invadopodia rosettes in Met-transformed cells and the specific uncoupling of cortactin from Gab1 abrogates invadopodia biogenesis and cell invasion downstream from the Met receptor tyrosine kinase. Met localizes to invadopodia along with cortactin and promotes phosphorylation of cortactin. These findings provide insights into the molecular mechanisms of invadopodia formation and identify Gab1 as a scaffold protein involved in this process. Journal of Cell Science Key words: Invadopodia, Met RTK, Gab1, Cortactin, Matrix remodeling, Cell invasion Introduction Molecular mechanisms leading to invadopodia biogenesis are Metastasis is the major cause of cancer-related mortality. During only beginning to emerge. Invadopodia-like cellular structures the initial steps of metastatic dissemination, some cancer cells with the capacity to degrade ECM were originally identified in acquire the ability to remodel extracellular matrix (ECM), invade chicken embryonic fibroblasts transformed by Rous sarcoma surrounding tissue locally, intravasate into lymphatic and blood virus (Chen, 1989), and were linked with constitutive activation microvasculature by breaking basement membranes (BM) of the of the v-Src oncogene (Hauck et al., 2002). Since then, many vessels and extravasate at distant sites (Chaffer and Weinberg, studies have established a role for increased Src kinase activity in 2011). Enhanced invasive capacity of many such cancer cells, the formation of invadopodia in cancer cells and in invadopodia- in particular carcinomas, is linked to their ability to form like structures of transformed fibroblasts, which are often invadopodia, specialized actin-rich membrane protrusions that referred to as podosomes (Ayala et al., 2009; Bowden et al., penetrate and remodel the ECM (Buccione et al., 2009; Gimona, 2006; Webb et al., 2007; Oikawa et al., 2008; Balzer et al., 2010; 2008), and that are much like podosomes formed in macrophages Kelley et al., 2010; Mader et al., 2011). and osteoclasts (Linder, 2007). Consequently, these invasive In addition to Src, other non-receptor tyrosine kinases, Abl cancer cells can use invadopodia as functional structures to and Arg, localize to invadopodia, and are involved in biogenesis perforate the basement membranes and guide the cell body into of these cellular structures in MDA-MB-231 breast carcinoma blood vessels (Schoumacher et al., 2010). cells (Mader et al., 2011; Smith-Pearson et al., 2010). Activation of the epidermal growth factor (EGF) as well as platelet derived growth factor (PDGF) receptor tyrosine kinases (RTK) also This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), promotes invadopodia biogenesis (Eckert et al., 2011; Mader which permits unrestricted non-commercial use, distribution and reproduction in any medium et al., 2011). These findings raise the possibility that multiple provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms. receptor tyrosine kinases, when deregulated in cancer, converge Met RTK induces invadopodia through Gab1 2941 signals to promote invadopodia biogenesis contributing to these structures and interacts directly with cortactin, a key metastatic progression. regulator of actin dynamics within invadopodia. We demonstrate The inner structure of invadopodia consists of an actin-rich core, that Met colocalizes with cortactin to invadopodia, and that Met the formation of which is regulated by actin regulatory proteins, activity contributes to increased tyrosine phosphorylation of protein kinases, as well as regulators of lipid metabolism (Murphy cortactin independent of Src kinase. By structure–function and Courtneidge, 2011). During invadopodia formation in analysis, we have established that a Gab1–cortactin interaction is response to EGF, actin polymerization is promoted following required for assembly of functional invadopodia, in response to cortactin tyrosine phosphorylation and localized release of the oncogenic Met signals. actin severing protein, cofilin (Oser et al., 2009). Src kinase also promotes tyrosine phosphorylation of cortactin (Bowden et al., Results 2006), as well as the scaffold protein Tks5 (Blouw et al., 2008; Tpr-Met induces formation of invadopodia rosettes in Seals et al., 2005). Tks5 recruits the adaptor protein, Nck, to form a fibroblasts trimeric complex (Stylli et al., 2009), which activates Wiscott– Recent studies have suggested that invasive and metastatic Aldrich syndrome protein (N-WASP) allowing recruitment of potential of cancer cells and malignantly transformed fibroblasts Arp2/3 to promote branched actin nucleation (Yamaguchi et al., is tightly linked with the ability of these cells to produce 2005). Downstream from Src, a Tks5 protein complex is recruited invadopodia (Gimona, 2008; Buccione et al., 2009; Schoumacher to phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P2]-rich et al., 2010). Therefore it is possible that malignant phenotypes, membrane regions through its phox homology (PX) domain and tumorigenicity and metastatic potential of cells transformed by initiates invadopodia biogenesis (Oikawa et al., 2008). oncogenic variants of the Met receptor are at least in part due to The Met RTK [also known as hepatocyte growth factor the acquired ability of these cells to produce invadopodia or (HGF) receptor] is a proto-oncogene often implicated in cancer similar actin-rich proteolytically active membrane protrusions (Birchmeier et al., 2003). In normal tissues, Met and its ligand, that enable remodeling of ECM. To investigate this possibility, HGF, activate signals that induce epithelial cell dispersal, we used Fischer rat 3T3 (FR3T3) fibroblasts transformed with the epithelial remodeling and invasive growth, which are important oncogenic variant of the Met receptor, Tpr-Met. Upon Tpr-Met- during development (Birchmeier et al., 2003). Met exerts an mediated transformation, FR3T3 fibroblasts acquire many invasive morphogenic program primarily through the scaffold features of malignantly transformed cancer cells, including the protein GRB2-associated-binding protein 1 (Gab1). Gab1 contains ability to invade through the ECM, as well as to develop tumors a pleckstrin homology (PH) domain, which tethers Gab1 to and metastases in nude mice (Fixman et al., 1996; Fixman et al., membranes through interactions with PtdIns(3,4,5)P3 (Maroun 1997; Saucier et al., 2002). In line with our previous findings, et al., 1999) and is recruited to and phosphorylated on multiple control FR3T3 cells used in this study spread and formed tyrosine residues by an activated Met receptor (Birchmeier et al., a contact-inhibited monolayer in culture, whereas FR3T3 2003; Peschard et al., 2007). Upon phosphorylation, these residues fibroblasts transformed with Tpr-Met developed a distinct serve as docking sites for numerous SH2-domain-containing elongated cell morphology, formed foci, lost contact inhibition adaptor and signaling proteins, including Crk, Nck, P85 subunit and acquired increased migratory and invasive capacity (Fig. 1) Journal of Cell Science of PI3K, Shp2 and PLCc (Abella et
Load more

Recommended publications
  • Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
    Leukemia (2010) 24, 756–764 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells A Pellagatti1, M Cazzola2, A Giagounidis3, J Perry1, L Malcovati2, MG Della Porta2,MJa¨dersten4, S Killick5, A Verma6, CJ Norbury7, E Hellstro¨m-Lindberg4, JS Wainscoat1 and J Boultwood1 1LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK; 2Department of Hematology Oncology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany; 4Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 5Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; 6Albert Einstein College of Medicine, Bronx, NY, USA and 7Sir William Dunn School of Pathology, University of Oxford, Oxford, UK To gain insight into the molecular pathogenesis of the the World Health Organization.6,7 Patients with refractory myelodysplastic syndromes (MDS), we performed global gene anemia (RA) with or without ringed sideroblasts, according to expression profiling and pathway analysis on the hemato- poietic stem cells (HSC) of 183 MDS patients as compared with the the French–American–British classification, were subdivided HSC of 17 healthy controls. The most significantly deregulated based on the presence or absence of multilineage dysplasia. In pathways in MDS include interferon signaling, thrombopoietin addition, patients with RA with excess blasts (RAEB) were signaling and the Wnt pathways. Among the most signifi- subdivided into two categories, RAEB1 and RAEB2, based on the cantly deregulated gene pathways in early MDS are immuno- percentage of bone marrow blasts.
    [Show full text]
  • The Wiskott-Aldrich Syndrome: the Actin Cytoskeleton and Immune Cell Function
    Disease Markers 29 (2010) 157–175 157 DOI 10.3233/DMA-2010-0735 IOS Press The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function Michael P. Blundella, Austen Wortha,b, Gerben Boumaa and Adrian J. Thrashera,b,∗ aMolecular Immunology Unit, UCL Institute of Child Health, London, UK bDepartment of Immunology, Great Ormond Street Hospital NHS Trust, Great Ormond Street, London, UK Abstract. Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive primary immunodeficiency characterised by immune dysregulation, microthrombocytopaenia, eczema and lymphoid malignancies. Mutations in the WAS gene can lead to distinct syndrome variations which largely, although not exclusively, depend upon the mutation. Premature termination and deletions abrogate Wiskott-Aldrich syndrome protein (WASp) expression and lead to severe disease (WAS). Missense mutations usually result in reduced protein expression and the phenotypically milder X-linked thrombocytopenia (XLT) or attenuated WAS [1–3]. More recently however novel activating mutations have been described that give rise to X-linked neutropenia (XLN), a third syndrome defined by neutropenia with variable myelodysplasia [4–6]. WASP is key in transducing signals from the cell surface to the actin cytoskeleton, and a lack of WASp results in cytoskeletal defects that compromise multiple aspects of normal cellular activity including proliferation, phagocytosis, immune synapse formation, adhesion and directed migration. Keywords: Wiskott-Aldrich syndrome, actin polymerization, lymphocytes,
    [Show full text]
  • The Wnt Pathway Scaffold Protein Axin Promotes Signaling Specificity by Suppressing Competing Kinase Reactions
    bioRxiv preprint doi: https://doi.org/10.1101/768242; this version posted September 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The Wnt pathway scaffold protein Axin promotes signaling specificity by suppressing competing kinase reactions Maire Gavagan1,2, Erin Fagnan1,2, Elizabeth B. Speltz1, and Jesse G. Zalatan1,* 1Department of Chemistry, University of Washington, Seattle, WA 98195, USA 2These authors contributed equally to this work *Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/768242; this version posted September 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract GSK3β is a multifunctional kinase that phosphorylates β-catenin in the Wnt signaling network and also acts on other protein targets in response to distinct cellular signals. To test the long-standing hypothesis that the scaffold protein Axin specifically accelerates β-catenin phosphorylation, we measured GSK3β reaction rates with multiple substrates in a minimal, biochemically-reconstituted system. We observed an unexpectedly small, ~2-fold Axin-mediated rate increase for the β-catenin reaction. The much larger effects reported previously may have arisen because Axin can rescue GSK3β from an inactive state that occurs only under highly specific conditions.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • CK1 Is Required for a Mitotic Checkpoint That Delays Cytokinesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Current Biology 23, 1920–1926, October 7, 2013 ª2013 Elsevier Ltd All rights reserved http://dx.doi.org/10.1016/j.cub.2013.07.077 Report CK1 Is Required for a Mitotic Checkpoint that Delays Cytokinesis Alyssa E. Johnson,1 Jun-Song Chen,1 isoforms were detected, which collapsed into a discrete ladder and Kathleen L. Gould1,* upon phosphatase treatment (Figure 1A, lanes 1 and 2). These 1Department of Cell and Developmental Biology, Vanderbilt bands are ubiquitinated isoforms because they collapse into a University School of Medicine, Nashville, TN 37232, USA single band in the absence of dma1+ (Figure 1A, lane 4) and Dma1 is required for Sid4 ubiquitination [6]. In dma1D cells, a single slower-migrating form of Sid4 was detected, which Summary was collapsed by phosphatase treatment, indicating that Sid4 is phosphorylated in vivo (Figure 1A, lanes 3 and 4). In vivo Failure to accurately partition genetic material during cell radiolabeling experiments validated Sid4 as a phosphoprotein division causes aneuploidy and drives tumorigenesis [1]. and revealed that Sid4 is phosphorylated on serines and thre- Cell-cycle checkpoints safeguard cells from such catastro- onines (see Figures S1A–S1C available online). The constitu- phes by impeding cell-cycle progression when mistakes tive presence of an unmodified Sid4 isoform indicates that arise. FHA-RING E3 ligases, including human RNF8 [2] and only a subpopulation of Sid4 is modified (Figure 1A). Collec- CHFR [3] and fission yeast Dma1 [4], relay checkpoint signals tively, these data indicate that Sid4 is ubiquitinated and phos- by binding phosphorylated proteins via their FHA domains phorylated in vivo.
    [Show full text]
  • TLR4 Endocytic Trafficking in Macrophages Modulates TLR4
    Glia Maturation Factor-γ Negatively Modulates TLR4 Signaling by Facilitating TLR4 Endocytic Trafficking in Macrophages This information is current as Wulin Aerbajinai, Kevin Lee, Kyung Chin and Griffin P. of September 28, 2021. Rodgers J Immunol 2013; 190:6093-6103; Prepublished online 15 May 2013; doi: 10.4049/jimmunol.1203048 http://www.jimmunol.org/content/190/12/6093 Downloaded from References This article cites 47 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/190/12/6093.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Glia Maturation Factor-g Negatively Modulates TLR4 Signaling by Facilitating TLR4 Endocytic Trafficking in Macrophages Wulin Aerbajinai, Kevin Lee, Kyung Chin, and Griffin P. Rodgers TLR4 signaling must be tightly regulated to provide both effective immune protection and avoid inflammation-induced pathology. Thus, the mechanisms that negatively regulate the TLR4-triggered inflammatory response are of particular importance.
    [Show full text]
  • A Network Model of Early Events in Epidermal Growth Factor Receptor Signaling That Accounts for Combinatorial Complexity Michael L
    BioSystems 83 (2006) 136–151 A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity Michael L. Blinov, James R. Faeder, Byron Goldstein, William S. Hlavacek ∗ Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA Received 8 January 2005; received in revised form 6 May 2005; accepted 21 June 2005 Abstract We consider a model of early events in signaling by the epidermal growth factor (EGF) receptor (EGFR). The model includes EGF, EGFR, the adapter proteins Grb2 and Shc, and the guanine nucleotide exchange factor Sos, which is activated through EGF- induced formation of EGFR–Grb2–Sos and EGFR–Shc–Grb2–Sos assemblies at the plasma membrane. The protein interactions involved in signaling can potentially generate a diversity of protein complexes and phosphoforms; however, this diversity has been largely ignored in models of EGFR signaling. Here, we develop a model that accounts more fully for potential molecular diversity by specifying rules for protein interactions and then using these rules to generate a reaction network that includes all chemical species and reactions implied by the protein interactions. We obtain a model that predicts the dynamics of 356 molecular species, which are connected through 3749 unidirectional reactions. This network model is compared with a previously developed model that includes only 18 chemical species but incorporates the same scope of protein interactions. The predictions of this model are reproduced by the network model, which also yields new predictions. For example, the network model predicts distinct temporal patterns of autophosphorylation for different tyrosine residues of EGFR.
    [Show full text]
  • HER2 Stabilizes EGFR and Itself by Altering Autophosphorylation Patterns in a Manner That Overcomes Regulatory Mechanisms and Pr
    Oncogene (2013) 32, 4169–4180 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling Z Hartman1, H Zhao1 and YM Agazie1,2 One of the causes of breast cancer is overexpression of the human epidermal growth factor receptor 2 (HER2). Enhanced receptor autophosphorylation and resistance to activation-induced downregulation have been suggested as mechanisms for HER2-induced sustained signaling and cell transformation. However, the molecular mechanisms underlying these possibilities remain incompletely understood. In the current report, we present evidence that show that HER2 overexpression does not lead to receptor hyper-autophosphorylation, but alters patterns in a manner that favors receptor stability and sustained signaling. Specifically, HER2 overexpression blocks epidermal growth factor receptor (EGFR) tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and Grb2, respectively, whereas promoting phosphorylation on Y1173, the known docking site of the Gab adaptor proteins and phospholipase C gamma. Under these conditions, HER2 itself is phosphorylated on Y1221/1222, with no known role, and on Y1248 that corresponds to Y1173 of EGFR. Interestingly, suppressed EGFR autophosphorylation on the Grb2 and c-Cbl-binding sites correlated with receptor stability and sustained signaling, suggesting that HER2 accomplishes these tasks by altering autophosphorylation patterns. In conformity with these findings, mutation of the Grb2-binding site on EGFR (Y1068F–EGFR) conferred resistance to ligand-induced degradation, which in turn induced sustained signaling, and increased cell proliferation and transformation.
    [Show full text]
  • Domain Requires the Gab2 Pleckstrin Homology Negative Regulation Of
    Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and This information is current as Phosphatidylinositol 3-Kinase: Evidence That of October 1, 2021. Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain Richard V. Parry, Gillian C. Whittaker, Martin Sims, Downloaded from Christine E. Edmead, Melanie J. Welham and Stephen G. Ward J Immunol 2006; 176:594-602; ; doi: 10.4049/jimmunol.176.1.594 http://www.jimmunol.org/content/176/1/594 http://www.jimmunol.org/ References This article cites 59 articles, 38 of which you can access for free at: http://www.jimmunol.org/content/176/1/594.full#ref-list-1 Why The JI? Submit online. by guest on October 1, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and Phosphatidylinositol 3-Kinase: Evidence That Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain1 Richard V.
    [Show full text]
  • Time Resolved Quantitative Phosphoproteomics Reveals Distinct Patterns of SHP2
    bioRxiv preprint doi: https://doi.org/10.1101/598664; this version posted April 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Time resolved quantitative phosphoproteomics reveals distinct patterns of SHP2 dependence in EGFR signaling Vidyasiri Vemulapalli1,2, Lily Chylek3, Alison Erickson4, Jonathan LaRochelle1,2, Kartik Subramanian3, Morvarid Mohseni5, Matthew LaMarche5, Michael G. Acker5, Peter K. Sorger3, Steven P. Gygi4, and Stephen C. Blacklow1,2* 1Department of Cancer Biology, Dana-Farber Cancer Institute Boston, MA 02115, USA 2Department of Biological Chemistry & Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA 3Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA 4Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA 5Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA *To whom correspondence should be addressed: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/598664; this version posted April 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract SHP2 is a protein tyrosine phosphatase that normally potentiates intracellular signaling by growth factors, antigen receptors, and some cytokines; it is frequently mutated in childhood leukemias and other cancers. Here, we examine the role of SHP2 in the responses of breast cancer cells to EGF by monitoring phosphoproteome dynamics when SHP2 is allosterically inhibited by the small molecule SHP099.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential As a Therapeutic Target
    cancers Review Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target Frank Aboubakar Nana 1,2 , Marie Vanderputten 1 and Sebahat Ocak 1,3,* 1 Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL et Dermatologie (PNEU), Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium; [email protected] (F.A.N.); [email protected] (M.V.) 2 Division of Pneumology, Cliniques Universitaires St-Luc, UCL, 1200 Brussels, Belgium 3 Division of Pneumology, CHU UCL Namur (Godinne Site), UCL, 5530 Yvoir, Belgium * Correspondence: [email protected]; Tel.: +32-2-764-9448; Fax: +32-2-764-9440 Received: 15 September 2019; Accepted: 24 October 2019; Published: 29 October 2019 Abstract: Small-cell lung cancer (SCLC) represents 15% of all lung cancers and it is clinically the most aggressive type, being characterized by a tendency for early metastasis, with two-thirds of the patients diagnosed with an extensive stage (ES) disease and a five-year overall survival (OS) as low as 5%. There are still no effective targeted therapies in SCLC despite improved understanding of the molecular steps leading to SCLC development and progression these last years. After four decades, the only modest improvement in OS of patients suffering from ES-SCLC has recently been shown in a trial combining atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, with carboplatin and etoposide, chemotherapy agents. This highlights the need to pursue research efforts in this field. Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is overexpressed and activated in several cancers, including SCLC, and contributing to cancer progression and metastasis through its important role in cell proliferation, survival, adhesion, spreading, migration, and invasion.
    [Show full text]